Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

310
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
310
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

364
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
364
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

431
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
431
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

360
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
360
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

663
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
663
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

196
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
196

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pulmonary changes after single dose interstitial brachytherapy for lung tumors.

Brachytherapy·2026
Same author

Fate-mapping infiltrating monocytes following experimental myocardial infarction revealsdifferentiation trajectories in the infarcted heart.

The Journal of clinical investigation·2026
Same author

Right Ventricular Metrics as End Points in Clinical Trials: A Review.

JAMA cardiology·2026
Same author

CRT upgrade improves frailty status in patients with HFrEF and RV pacing-a post hoc analysis of the BUDAPEST-CRT trial.

GeroScience·2026
Same author

Clinical course and outcomes of antibody-mediated rejection after heart transplant in the contemporary era.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

[The clinical significance and management of submacular hemorrhage].

Orvosi hetilap·2026

Related Experiment Video

Updated: Jan 7, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.9K

Apolipoprotein M in Right Heart Failure.

Mahmoud I Elesawy, Christina F Fu, Adeesh Parvathaneni

    Medrxiv : the Preprint Server for Health Sciences
    |December 25, 2025
    PubMed
    Summary

    Lower levels of Apolipoprotein M (ApoM) indicate worse outcomes in right heart failure (RHF). Restoring ApoM protects the heart and reduces liver congestion, highlighting its role in the heart-liver axis.

    More Related Videos

    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
    03:42

    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

    Published on: March 29, 2024

    1.9K
    Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
    09:40

    Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice

    Published on: May 13, 2019

    11.0K

    Related Experiment Videos

    Last Updated: Jan 7, 2026

    Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
    14:35

    Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

    Published on: April 17, 2021

    8.9K
    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
    03:42

    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

    Published on: March 29, 2024

    1.9K
    Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
    09:40

    Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice

    Published on: May 13, 2019

    11.0K

    Area of Science:

    • Cardiology
    • Hepatology
    • Biochemistry

    Background:

    • Right heart failure (RHF) causes hepatic congestion due to elevated central venous pressure.
    • Apolipoprotein M (ApoM), a high-density lipoprotein-bound lipocalin, transports sphingosine-1-phosphate (S1P), crucial for vascular integrity and inflammation modulation.
    • Low ApoM levels are linked to adverse outcomes in heart failure (HF), but its specific role in RHF remains unclear.

    Purpose of the Study:

    • To investigate the impact of RHF on circulating ApoM levels.
    • To determine the prognostic value of ApoM in RHF-related mortality.
    • To explore the functional role of ApoM in the cardio-hepatic axis.

    Main Methods:

    • Patients were categorized into normal, HF, or RHF groups based on right heart catheterization.
    • Serum ApoM and S1P levels were quantified using ELISA.
    • ApoM transgenic (Tg) and wild-type (WT) mice underwent pulmonary artery banding (PAB) or partial inferior vena cava ligation (pIVCL) to model RHF and hepatic congestion, respectively. Cardiac and hepatic tissues were analyzed.

    Main Results:

    • RHF patients exhibited the lowest ApoM levels, which inversely correlated with inflammatory markers.
    • Each 0.01 μM increase in ApoM was associated with a 6% reduction in mortality risk.
    • In mice, PAB reduced ApoM in WT mice; ApoM Tg mice showed attenuated RV remodeling and less hepatic congestion. However, ApoM Tg mice with pIVCL did not show improved liver pathology.

    Conclusions:

    • Circulating ApoM is reduced in both RHF patients and mice with RV dysfunction.
    • Lower ApoM levels are an independent predictor of adverse outcomes in RHF.
    • Restoring ApoM primarily benefits the heart, subsequently improving liver congestion, emphasizing its critical role in the heart-liver axis for RHF management.